8,677 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Bought by Creative Planning

Creative Planning acquired a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 8,677 shares of the company’s stock, valued at approximately $275,000.

A number of other large investors have also modified their holdings of the company. Covestor Ltd raised its holdings in IDEAYA Biosciences by 9,225.0% in the 1st quarter. Covestor Ltd now owns 1,119 shares of the company’s stock worth $49,000 after purchasing an additional 1,107 shares during the period. Quest Partners LLC acquired a new position in shares of IDEAYA Biosciences during the 2nd quarter worth approximately $41,000. Comerica Bank lifted its position in shares of IDEAYA Biosciences by 723.5% during the 1st quarter. Comerica Bank now owns 1,507 shares of the company’s stock valued at $66,000 after buying an additional 1,324 shares in the last quarter. Daiwa Securities Group Inc. grew its stake in IDEAYA Biosciences by 637.9% in the 2nd quarter. Daiwa Securities Group Inc. now owns 1,948 shares of the company’s stock valued at $68,000 after acquiring an additional 1,684 shares during the period. Finally, SG Americas Securities LLC purchased a new stake in IDEAYA Biosciences in the 1st quarter worth $101,000. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences Stock Up 4.3 %

IDEAYA Biosciences stock opened at $31.28 on Friday. IDEAYA Biosciences, Inc. has a 52-week low of $27.52 and a 52-week high of $47.74. The firm has a market cap of $2.70 billion, a PE ratio of -13.42 and a beta of 0.86. The company’s 50 day moving average is $32.23 and its two-hundred day moving average is $36.70.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.03. During the same period last year, the firm earned ($0.46) earnings per share. On average, equities research analysts anticipate that IDEAYA Biosciences, Inc. will post -2.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IDYA has been the topic of several recent analyst reports. Leerink Partnrs downgraded shares of IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 5th. Leerink Partners lowered IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $41.00 to $27.00 in a research note on Tuesday, November 5th. Oppenheimer restated an “outperform” rating and issued a $53.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday, October 29th. Lifesci Capital raised IDEAYA Biosciences to a “strong-buy” rating in a research note on Monday, July 29th. Finally, JPMorgan Chase & Co. reduced their price objective on IDEAYA Biosciences from $69.00 to $66.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. Two analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, IDEAYA Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $53.91.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.